Therapeutic Options for HER2-Positive, Early-Stage Breast Cancer After Neoadjuvant Therapy
In recent years, the development of HER2-targeted therapies such as pertuzumab and trastuzumab have significantly improved the natural history of HER2-positive breast cancer. READ MORE »
